Articles

Atrial fibrillation (AF), long considered the most common condition leading to an irregular heartbeat, is a growing and...

Watchman, LAA occluder, atrial fibrillation

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably Dec. 11 in a 13-1 vote that the benefits of the Watchman...

topera 3-d ep lab atrial fibrillation therapies mapping/imaging systems

Topera Inc. shared the results of an independent evaluation of its diagnostic system’s ability to improve atrial...

laa occluders structural heart atrial fibrillation atricure atriclip exclusion

AtriCure Inc., a developer of solutions to treat atrial fibrillation, announced the U.S. Food and Drug Administration’s (FDA’s) approval to begin enrollment in a clinical study of AtriCure’s...

LAA occluder, Watchman

According to Millennium Research Group (MRG), the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's Watchman device will drive rapid growth in the market for...

Nationwide data show that although only about 12 percent of X-ray exams are for interventional cardiology or electrophysiology (EP) procedures, nearly 50 percent of a patient’s lifetime radiation...

 Endosense TactiCath

There have been several advances in electrophysiology (EP) technologies this past year, many of which were highlighted during the Heart Rhythm Society (HRS) 2013 scientific sessions earlier this...

New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF) sources and...

nContact Inc. said it received conditional approval for an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE...